<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Trials & Chemotherapy - Gynaecological Oncology Laboratory, HKU</title>
    <link rel="stylesheet" href="styles.css">
    <link href="https://fonts.googleapis.com/css2?family=Rock+Salt&family=Gochi+Hand&family=Handlee:wght@400;700&family=Caveat+Brush&display=swap" rel="stylesheet">
</head>
<body>
    <header class="header">
        <nav class="nav">
            <div class="nav-brand">
                <img src="logo/HKU_bilingual_logo.png" alt="The University of Hong Kong" class="university-logo">
                <div class="lab-info">
                    <h1>Gynaecological Oncology Laboratory</h1>
                    <p class="dept-name">Department of Obstetrics & Gynaecology</p>
                </div>
            </div>
            <ul class="nav-menu">
                <li><a href="index.html">Home</a></li>
                <li><a href="index.html#about">About</a></li>
                <li><a href="index.html#research">Research</a></li>
                <li><a href="team.html">Team</a></li>
                <li><a href="index.html#publications">Publications</a></li>
                <li><a href="http://localhost:8501" target="_blank" class="data-exploration-btn">Data</a></li>
                <li><a href="index.html#contact">Contact</a></li>
            </ul>
        </nav>
    </header>

    <main>
        <section class="hero-subpage">
            <div class="container">
                <div class="breadcrumb">
                    <a href="index.html">Home</a> > <span>Clinical Trials & Chemotherapy</span>
                </div>
                <h1>Clinical Trials & Chemotherapy</h1>
                <p class="subpage-subtitle">Comprehensive oncology treatment services with access to cutting-edge clinical trials and advanced chemotherapy protocols</p>
            </div>
        </section>

        <section class="section">
            <div class="container">
                <div class="content-layout">
                    <div class="main-content">
                        <h2 class="gloria-title">Clinical Excellence</h2>
                        <p>Our Clinical Trials & Chemotherapy program provides comprehensive medical oncology services with access to the latest therapeutic advances through clinical trials. We administered 2,407 courses of chemotherapy in 2023, serving as a major regional center for gynecological cancer treatment and clinical research.</p>

                        <h2 class="gloria-title">Treatment Volume (2023)</h2>
                        <div class="stats-grid">
                            <div class="stat-card">
                                <h3>2,407</h3>
                                <p>Total Chemotherapy Courses</p>
                            </div>
                            <div class="stat-card">
                                <h3>504</h3>
                                <p>Patients Treated</p>
                            </div>
                            <div class="stat-card">
                                <h3>62</h3>
                                <p>PARP Inhibitor Patients</p>
                            </div>
                            <div class="stat-card">
                                <h3>19</h3>
                                <p>Oral Chemotherapy Patients</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Treatment Modalities</h2>
                        <div class="treatment-breakdown">
                            <div class="treatment-category">
                                <h3>Inpatient Chemotherapy (552 courses)</h3>
                                <ul>
                                    <li><strong>Carboplatin/Paclitaxel:</strong> 331 courses (most common regimen)</li>
                                    <li><strong>EMA-CO:</strong> 21 courses (gestational trophoblastic neoplasia)</li>
                                    <li><strong>Topotecan:</strong> 22 courses (recurrent disease)</li>
                                    <li><strong>Pembrolizumab/Lenvatinib:</strong> 15 courses (immunotherapy combination)</li>
                                </ul>
                            </div>

                            <div class="treatment-category">
                                <h3>Outpatient Chemotherapy (1,855 courses)</h3>
                                <ul>
                                    <li><strong>Carboplatin/Paclitaxel:</strong> 578 courses</li>
                                    <li><strong>Bevacizumab:</strong> 76 courses (anti-angiogenesis therapy)</li>
                                    <li><strong>Cisplatin:</strong> 66 courses</li>
                                    <li><strong>Topotecan:</strong> 61 courses</li>
                                    <li><strong>Pembrolizumab:</strong> 45 courses</li>
                                </ul>
                            </div>
                        </div>

                        <h2 class="gloria-title">Targeted Therapy & Immunotherapy</h2>
                        <div class="targeted-therapies">
                            <div class="therapy-category">
                                <h3>PARP Inhibitors (62 patients)</h3>
                                <div class="drug-details">
                                    <div class="drug-item">
                                        <strong>Niraparib:</strong> 309 outpatient courses
                                        <p>Used primarily for maintenance therapy in ovarian cancer patients with BRCA mutations or homologous recombination deficiency</p>
                                    </div>
                                    <div class="drug-item">
                                        <strong>Olaparib:</strong> 271 outpatient courses
                                        <p>First-line maintenance and treatment of BRCA-mutated ovarian, fallopian tube, and peritoneal cancers</p>
                                    </div>
                                </div>
                            </div>

                            <div class="therapy-category">
                                <h3>Immunotherapy Combinations</h3>
                                <div class="drug-details">
                                    <div class="drug-item">
                                        <strong>Pembrolizumab/Lenvatinib:</strong> 55 courses total
                                        <p>Combination immunotherapy and anti-angiogenic therapy for recurrent endometrial cancer</p>
                                    </div>
                                    <div class="drug-item">
                                        <strong>Dostarlimab combinations:</strong> 9 courses
                                        <p>Anti-PD-1 therapy for microsatellite instability-high tumors</p>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <h2 class="gloria-title">Clinical Trials Program</h2>
                        <div class="research-areas">
                            <div class="research-area">
                                <h3>International Collaborations</h3>
                                <p>Active participation in major international clinical trial networks including GOG (Gynecologic Oncology Group), ENGOT (European Network of Gynecological Oncological Trial Groups), and GCIG (Gynecologic Cancer InterGroup) studies.</p>
                            </div>
                            <div class="research-area">
                                <h3>Phase II/III Studies</h3>
                                <p>Leading investigator site for multiple phase II and III studies, including the landmark intraperitoneal carboplatin study published in NEJM Evidence 2023.</p>
                            </div>
                            <div class="research-area">
                                <h3>Investigational Agents</h3>
                                <p>Early access programs for novel agents including durvalumab/placebo + olaparib/placebo studies and other cutting-edge therapeutic combinations.</p>
                            </div>
                            <div class="research-area">
                                <h3>Translational Research Integration</h3>
                                <p>Integration of translational research with clinical trials, including biomarker studies, pharmacokinetic analyses, and companion diagnostic development.</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Specialized Treatment Areas</h2>
                        <div class="specialized-treatments">
                            <div class="treatment-area">
                                <h3>Gestational Trophoblastic Neoplasia</h3>
                                <p><strong>EMA-CO Protocol:</strong> 22 total courses (21 inpatient, 1 outpatient)</p>
                                <p>Specialized center for high-risk gestational trophoblastic neoplasia with excellent cure rates</p>
                            </div>

                            <div class="treatment-area">
                                <h3>Recurrent Disease Management</h3>
                                <p><strong>Topotecan:</strong> 83 total courses for platinum-resistant ovarian cancer</p>
                                <p><strong>Liposomal Doxorubicin:</strong> 78 total courses with bevacizumab combinations</p>
                            </div>

                            <div class="treatment-area">
                                <h3>Rare Tumor Expertise</h3>
                                <p>Specialized protocols for rare gynecological malignancies including germ cell tumors, sex cord-stromal tumors, and sarcomas</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Quality Assurance & Safety</h2>
                        <div class="safety-measures">
                            <h3>Patient Safety Protocols</h3>
                            <ul>
                                <li>Comprehensive pre-treatment assessment and monitoring</li>
                                <li>Standardized adverse event reporting and management</li>
                                <li>Regular safety monitoring committee reviews</li>
                                <li>Multidisciplinary treatment planning and review</li>
                            </ul>

                            <h3>Clinical Trial Standards</h3>
                            <ul>
                                <li>Good Clinical Practice (GCP) compliance</li>
                                <li>Regulatory approval processes</li>
                                <li>Ethics committee oversight</li>
                                <li>Data management and safety monitoring</li>
                            </ul>
                        </div>
                    </div>

                    <div class="sidebar">
                        <div class="sidebar-card">
                            <h3>Treatment Statistics</h3>
                            <ul>
                                <li>287 outpatient chemotherapy patients</li>
                                <li>217 inpatient chemotherapy patients</li>
                                <li>19 oral chemotherapy patients</li>
                                <li>62 PARP inhibitor patients</li>
                                <li>Multiple clinical trials active</li>
                            </ul>
                        </div>

                        <div class="sidebar-card">
                            <h3>Clinical Services</h3>
                            <p><strong>Chemotherapy Clinic:</strong> 1 session per week</p>
                            <p><strong>Day Chemotherapy:</strong> 5 days per week</p>
                            <p><strong>Clinical Trials Office:</strong> Dedicated research team</p>
                        </div>

                        <div class="sidebar-card">
                            <h3>Research Publications</h3>
                            <div class="publication-item">
                                <h4>Intraperitoneal Carboplatin Trial</h4>
                                <p>NEJM Evid. 2023;2(5)</p>
                            </div>
                            <div class="publication-item">
                                <h4>International Trial Participation</h4>
                                <p>Multiple GOG and ENGOT studies</p>
                            </div>
                        </div>

                        <div class="sidebar-card">
                            <h3>Specialized Programs</h3>
                            <ul>
                                <li>PARP inhibitor clinic</li>
                                <li>Immunotherapy monitoring</li>
                                <li>GTN treatment protocols</li>
                                <li>Rare tumor management</li>
                                <li>Fertility preservation</li>
                            </ul>
                        </div>

                        <div class="sidebar-card">
                            <h3>Clinical Team</h3>
                            <p><strong>Clinical Oncologists:</strong></p>
                            <p>Dr. Yuen Kwok Keung (Chief of Service)</p>
                            <p>Dr. Siu Wai Kwan Steven</p>
                            <p><strong>Medical Oncologist:</strong></p>
                            <p>Professor Kwong Yok Lam</p>
                        </div>
                    </div>
                </div>
            </div>
        </section>
    </main>

    <footer class="footer">
        <div class="container">
            <p>&copy; 2024 Gynaecological Oncology Laboratory, Department of Obstetrics & Gynaecology, The University of Hong Kong. All rights reserved.</p>
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>